Latest at Cipla

Technology will play an indispensable role in shaping the healthcare systems of the future. In the past two years, it has certainly helped the stakeholders adapt to disruptions almost overnight and become more efficient

Endura and all other associated trademarks would be part of the acquisition. CHL will initiate the distribution and marketing of the Endura Mass pending the closure of the proposed acquisition.

The company has signed definitive agreements with Achira Labs for the purpose, Cipla said in a regulatory filing

Post completion of the deal, Cipla’s total stake in GoApptiv will increase to 22.02% on a fully diluted basis. The investment will be made in equity shares and compulsorily convertible preference shares and is likely to be completed within 30 days or such other date mutually agreed between the parties subject to fulfillment of necessary closing conditions, Cipla said in a statement.

One of the major successes of Hamied was building a strong US business, despite Cipla being a late entrant. Hamied said this was made possible by pursuing selective yet complex generic portfolios. Cipla entered US in a big way with the strategic acquisitions of two generic companies, InvaGen Pharma and Exelan Pharma, for $550 mn in 2015.

ET Businesswoman of the Year 2021: Samina Hamied - The woman who carries forward a storied legacy, seeking profit, but never at the cost of values.

“I am humbled and honoured to receive the ET’s Businesswoman of the Year Award. This recognition belongs to each and every one of our 25,000 employees who stand with Cipla, putting patients’ interests before their own and upholding our purpose of Caring for Life,” Hamied, executive vice-chairperson, Cipla, told ET.

Cipla, which has seen a generational change in its leadership, draws 40 per cent of its revenues from India and 21 per cent from the US market.

Cipla the third largest pharma company in India, present in more than 80 countries with over 47 manufacturing facilities is now focusing more towards difficult to manufacture complex drugs and injectables in segments such as respiratory and cancer. The company is also looking to grow its presence in the US. To discuss the growth outlook, CNBC-TV18 spoke to Umang Vohra, MD & Global CEO of Cipla.

The article has been authored by Samina Hamied, executive vice-chairperson, Cipla and vice-president, Indian Pharmaceutical Alliance.

The Indian pharmaceutical industry ranks third worldwide for production by volume and caters to 20% of the global demand in the generic market in terms of volume.(AP)